Rare disease
Retinitis Pigmentosa
Clinical trials recruiting in Australia for Retinitis Pigmentosa, a rare disease, as the public registries list them.
Also called: RP; Tapetoretinal degeneration
Follow this condition Browse A to Z Browse by body system
At a glance
6 trials recruiting in Australia
70 trials recruiting overseas
1-5 / 10 000 (Point prevalence, United States, Validated) prevalence
Adolescent; Adult; Childhood age of onset
11 October 2026 date last checked
Trials in Australia
This Australian count is likely to be on the low side. It counts the trials this site files under this condition; the registry’s own search is broader and also returns closely related conditions, some of which have their own page here. If you are searching widely, check the registry as well — every trial below links to its own record.
-
Recruiting Not a phased study
Study for people with Retinitis Pigmentosa
Where- Online Patient Enrollment System, Sydney — Recruiting
Who can join Age child, adult, older adult. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor Sanford HealthTimelineStarted 1 July 2010 Today 16 October 2026 Estimated completion 1 December 2100NCT01793168 · Checked 11 October 2026
-
By invitation Not a phased study
Study for people with Retinitis Pigmentosa
WhereNo Australian site on this record is listed as recruiting right now, even though the trial itself is open. Check with the site or the official record before travelling.
- Centre for Eye Research Australia, Melbourne E. (VIC) — this site's status is not stated on the record
Who can join Age child, adult, older adult. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor Center for Eye Research AustraliaTimelineStarted 9 December 2021 Today 16 October 2026 Estimated completion 9 December 2026NCT05158049 · Checked 11 October 2026
-
Recruiting Not a phased study
Study for people with Retinitis Pigmentosa
Where- Centre for Eye Research Australia, East Melbourne (VIC) — Recruiting
Who can join Age 4 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor Jaeb Center for Health ResearchTimelineStarted 11 May 2023 Today 16 October 2026 Estimated completion 15 December 2029NCT05589714 · Checked 11 October 2026
-
Recruiting Phase 2
Phase 2 study for people with Retinitis Pigmentosa
Where- Save Sight Institute, Sydney (NSW) — Recruiting
- Queensland Eye Institute, Woolloongabba (QLD) — Recruiting
- Royal Adelaide Hospital, Adelaide (SA) — Recruiting
- Cerulea Clinical Trials, East Melbourne (VIC) — Recruiting
- Lions Eye Institute, Nedlands (WA) — Recruiting
Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor Kiora Pharmaceuticals, Inc.TimelineStarted 29 August 2025 Today 16 October 2026 Estimated completion 1 August 2027NCT06628947 · Checked 11 October 2026
-
Not yet recruiting Not a phased study
Study for people with Retinitis Pigmentosa
WhereNo Australian site on this record is listed as recruiting right now, even though the trial itself is open. Check with the site or the official record before travelling.
- Centre for Eye Research Australia, Melbourne (VIC) — this site's status is not stated on the record
Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers See the criteria below.Sponsor Center for Eye Research AustraliaTimelineStarted 1 April 2025 Today 16 October 2026 Estimated completion 31 December 2027NCT06908161 · Checked 11 October 2026
-
Recruiting Not a phased study
Study for people with Retinitis Pigmentosa
Where- Sydney Eye Hospital, Sydney (NSW) — Recruiting
Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.Sponsor Science CorporationTimelineStarted 22 April 2026 Today 16 October 2026 Estimated completion 1 March 2029NCT07266584 · Checked 11 October 2026
Trials overseas
70 trials for this disease are open to new participants outside Australia, as ClinicalTrials.gov listed them on 11 October 2026. Voxsanity does not publish a page for any of them; the searches below reach them at the registry.
These overseas counts are likely too high. They come from the registry’s own search, which expands a condition name to related conditions, so some of the trials counted are for a different disease in the same family.
Search ClinicalTrials.gov Search the WHO registry portal Joining a trial overseas
Trials not shown here
Some Australian trials are registered only on the Australian New Zealand Clinical Trials Registry and are not shown here. Search them at Australian Clinical Trials.
Key facts
Orphadata Science: Free access data from Orphanet. © INSERM 1999. Available on https://www.orphadata.com. Used under CC BY 4.0. Source: Orphanet / Orphadata (orphadata.com).
About Retinitis Pigmentosa
The text below is reproduced exactly as its source published it. It has not been edited, shortened or rewritten.
Retinitis pigmentosa is a group of related eye disorders that cause progressive vision loss. These disorders affect the retina, which is the layer of light-sensitive tissue at the back of the eye. In people with retinitis pigmentosa, vision loss occurs as the light-sensing cells of the retina gradually deteriorate. The first sign of retinitis pigmentosa is usually a loss of night vision, which becomes apparent in childhood. Problems with night vision can make it difficult to navigate in low light. Later, the disease causes blind spots to develop in the side (peripheral) vision. Over time, these blind spots merge to produce tunnel vision. The disease progresses over years or decades to affect central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. In adulthood, many people with retinitis pigmentosa become legally blind. The signs and symptoms of retinitis pigmentosa are most often limited to vision loss. When the disorder occurs by itself, it is described as nonsyndromic. Researchers have identified several major types of nonsyndromic retinitis pigmentosa, which are usually distinguished by their pattern of inheritance: autosomal dominant, autosomal recessive, or X-linked. Less commonly, retinitis pigmentosa occurs as part of syndromes that affect other organs and tissues in the body. These forms of the disease are described as syndromic. The most common form of syndromic retinitis pigmentosa is Usher syndrome, which is characterized by the combination of vision loss and hearing loss beginning early in life. Retinitis pigmentosa is also a feature of several other genetic syndromes, including Bardet-Biedl syndrome; Refsum disease; and neuropathy, ataxia, and retinitis pigmentosa (NARP).
US source; availability in Australia may differ.
Source: MedlinePlus Genetics (medlineplus.gov), public domain (U.S. National Library of Medicine). Read the full source.
Sources and dates
- ClinicalTrials.gov – trial records, statuses and site lists
- MedlinePlus – the About text above, reproduced exactly
- Orphanet / Orphadata – prevalence, age of onset, inheritance, genes and alternative names, used under CC BY 4.0
- ClinicalTrials.gov processing date: 8 September 2026.
- This page last checked by Voxsanity: 11 October 2026.
Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.
Not medical advice.
Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.
Orphanet citation
Orphadata Science: Free access data from Orphanet. © INSERM 1999. Available on https://www.orphadata.com. Used under CC BY 4.0. Source: Orphanet / Orphadata (orphadata.com). Accessed 20 September 2026.
Retinitis Pigmentosa is one of the rare diseases tracked on the Voxsanity rare disease hub, where you can compare it with every other rare condition we follow and filter trials by country.
Tell us which conditions matter to you
We use requests to help decide what to add next. Telling us about a condition is not a promise that we will add it, and we cannot say when any condition might appear.